Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Alpharma Announces Agreement with Indian Firm Shasun to Develop and Manufacture Generic Prescription and API Products

By Pharmaceutical Processing | June 2, 2005

Alpharma Inc., has announced that it has entered into an agreement with Shasun Chemicals & Drugs Limited (“Shasun”), under which the Chennai-based global pharmaceutical company will develop, manufacture and supply generic prescription products and active pharmaceutical ingredients for exclusive sale by Alpharma. This agreement is expected to significantly accelerate the expansion of Alpharma’s global generic product pipeline in line with company strategy.

Under the agreement, Shasun will develop active pharmaceutical ingredients and final formulations, and manufacture finished products for exclusive sale by Alpharma worldwide. Alpharma will take responsibility for the regulatory filings and will own all intangible assets developed by the partnership. During the period of exclusive sales by Alpharma, the two companies will share profits and Alpharma will reimburse Shasun for certain development and manufacturing costs.

Ten products with global brand sales exceeding $20 billion are initially planned under this agreement, but additional products may be added over time. Product launches are scheduled to begin in 2007. The agreement with Shasun follows a similar development and manufacturing arrangement with Chennai-based Orchid Chemicals & Pharmaceuticals, Ltd. announced in February.

Shasun, incorporated in 1976 and headquartered in Chennai, India is primarily a manufacturer of APIs, intermediates and excipients. It is also engaged in contract research and contract manufacturing for major global pharmaceutical companies, and is the world’s largest producer of ibuprofen (bulk drug) and supplies about 15% of the U.S market requirements of the drug. In addition, the company is a leading company in the anti-inflammatory, anti- ulcerative and anesthetic segments.

Related Articles Read More >

A Zipline fixed-wing drone in the air drops a package
Cardinal Health starts Zipline drone deliveries of drugs and medical supplies
Pfizer logo
Pfizer to spend $120M to make COVID-19 oral treatment in U.S.
Image of MedTrace Pharma's P3 automated delivery system for 15-O water in action
MedTrace Pharma moves forward on 15 O-water imaging tech
coronavirus COVID-19 Pfizer
NIH starts evaluating second COVID-19 booster shots in adults

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards